• search
Country
CAPTCHA This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Analytical Development and Manufacturing Services

Analytical Development and Manufacturing Services

We offer fit-for-purpose analytical solutions.

We provide physiochemical characterization services ranging from protein structure confirmation to amino acid content detection. We also quantify free cysteines and detect product impurities such as glycation and deamidation.

Backed by our strong protein chemistry background, we enable ‘Finger-Print’ protein structure and functional characterization for proteins from naked proteins to hyper-glycosylated or derivatized proteins.

Our biological characterization capability enables a sound understanding of the biological mechanism of action of the product. We can support a wide variety of biological assays including, cell-proliferation or killing, binding affinity, cell signaling, and viability or endpoint assays using both transformed cell lines and primary cells.

Speak to our experts

Physiochemical Characterization

We provide physiochemical characterization services ranging from protein structure confirmation to amino acid content detection. We also quantify free cysteines and detect product impurities such as glycation and deamidation.

The ability is based on a diverse platform of instruments and technologies supported by a fully-trained technical staff:

  • 21 CFR part 11 and GAMP compliant system-based labs
  • Comprehensive infrastructure to support orthogonal confirmation of product parameters
  • Experience across diverse protein expression systems

Catalog:

  • Primary structure: Intact mass and fragmented mass
  • Higher order structure: secondary and tertiary structure, melting point, disulfide linkage and free thiol
  • Post-translational modification: oligosaccharide profiling, oxidation, deamidation and cleavage
  • Product/process - related impurities: size and charge variant analysis
  • Technology: Mass spectrometry, HPLC, UPLC, spectroscopy, circular dichroism, fluorometry, DSC DLS, SEC MALS, ion chromatography, CEIEF, CESDS and solo VpE
  • Protein: mAb, Fab, fusion protein, cytokine, enzyme, hormone, hyperglycosylated proteins and derivatized proteins

Biological Characterization

Our capability in luminescence and fluorescence-based assays and flow cytometry enables a wider reach of biological characterization. In addition, we also develop bio-assays for clinical sample analysis and immunogenicity assessment:

  • Development of bioassays and cell-based assay employing primary and derived cell lines
  • Expertise in luminescence, fluorescence and flow cytometry-based assay
  • Wide variety of cell signaling and endpoint assays – ADCC, CDC and proliferation
  • Ability to handle clinical samples

Catalog:

  • Signaling: GPCR, calcium release, kinase and phosphorylation
  • Binding: Direct/indirect ELISA, competition ELISA and surface plasmon resonance (BIAcore)
  • Viability: ADCC, CDC and proliferation
  • PK/PD: Serum drug concentration, immunogenicity and neutralizing antibody
  • Technology: Luminescence and fluorescence-based methods, multicolor flow cytometry, microscopy and primary cell culture
  • Protein: mAb, Fab, fusion protein, cytokine, enzyme, hormone, hyperglycosylated proteins and derivatized proteins

Why Aurigene Pharmaceutical Services?

ALCOA+ driven quality systems

Diverse platform of instruments and technologies

Integrated approach to safety and quality management systems

In-house capability across the value chain with a trained scientific staff

Virtual Tour

 

Contact Us

Country
CAPTCHA This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
resourceMainImage

JUNE 28, 2022

Neoantigen Specific T cells For Cancer Immunotherapy

Neoantigen specific T cells for cellular cancer immunotherapy An effective anti-tumor immune response in human is marked by presence of T cells reactive against neoantigens. Neoantigens are HLA-bound unique peptides arise from tumor-specific somatic mutations. Neoantigens are highly immunogenic because they are not present in normal tissues and hence...

Read More
resourceMainImage

Building successful long-term partnerships with CDMOs from early drug discovery through commercialization

Building successful long-term partnerships with CDMOs from early drug discovery through commercialization Maximizing efficiency in drug research, development, and manufacturing is crucial for turning new innovations into therapeutic and financial benefits. Over the past couple of decades, pharmaceutical companies have increasingly turned to contr...

Read More
resourceMainImage

Technology meets sustainability - How a complex API development process goes green

We are always looking for ways to enhance the sustainability of our products and services. Our team successfully developed a scalable manufacturing process for the API product of one of our Biotech clients using eco-friendly manufacturing technologies. Read the case study to learn more. ...

Read More

Alternate end-game strategies towards Nirmatrelvir synthesis: Defining a continuous flow process for the preparation of an anti-COVID drug

2023

Scalable alternate end-game strategies for the synthesis of the anti-COVID drug molecule Nirmatrelvir (1,PF-07321332) have been described. The first involves a direct synthesis of 1 via amidation of the carboxylic acid 7 (suitably activated as a mixed anhydride with either pivaloyl chloride or T3P) with the ...

Read More
View All
×

You are about to leave Aurigene Pharmaceutical Services and affiliates website. Aurigene Pharmaceutical Services assumes no responsibility for the information presented on the external website or any further links from such sites. These links are presented to you only as a convenience, and the inclusion of any link does not imply endorsement by Aurigene Pharmaceutical Services.

If you wish to continue to this external website, click Proceed.

ProceedBack